BiondVax Announces Second Quarter 2015 Financial Results and Update Nes Ziona, Israel

Quarter 2015 Financial Results and Update

Ziona, Israel, August 24, 2015 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical

stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases,

today announced its financial results for the second quarter of 2015 and provided a business update.

Quarter 2015 Financial Summary

are in New Israel Shekels (NIS) and a convenience translation to US$ is provided, using the exchange rate of 3.769 as at June

Ron Babecoff, CEO of BiondVax Commented: "The second quarter of 2015 was very eventful for BiondVax, culminating in

a number of successes. A few weeks following our successful public offering on Nasdaq, we completed and reported successful results

for our BVX-006 trial. We showed that our universal flu vaccine enhanced antibody responses to multiple flu strains when administered

as a primer, and was safe and well tolerated. More than that, a few weeks later, we showed that participants who received our

vaccine in our 2012 trial, presented higher immunogenicity to the 2014-15 flu season strain - a strain which didn't exist

back then. Both these successful results are additional important data points, validating our work and further demonstrating the

universality of our vaccine and its potential for improving global public health. Our work is particularly poignant as the 2015/2016

flu season approaches."

terms of our efforts to broaden our shareholder base, I will be marketing our story to investors on non-deal roadshows, and presenting

at a number of investor conferences in New York, Las Vegas and Los Angeles, in the coming quarter. We see a number of near-term

catalysts, such as our EU funded study in Europe, and we are all very much looking forward to the coming few months. We believe

our upcoming efforts will further support our concept of the universal flu vaccine," concluded Dr. Babecoff.

is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain

protection against most human influenza virus strains, including both seasonal and pandemic flu strains.

BiondVax's technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins

to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Forward Looking Statements

press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such

as "expect," "believe," "intend," "plan," "continue," "may," "will,"

"anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements

involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events

and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected

by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug

development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred

to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which

was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking

OF COMPREHENSIVE INCOME (LOSS)